Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis

This study is a randomized, double-blind, multi-center, parallel, phase II clinical trial, aiming to evaluate the efficacy and safety of SHR-1139 injection for adult patients with psoriasis. The trial includes a 4-week screening period, a 52-week treatment period, and a 12-week safety follow-up period. Approximately 60 patients with psoriasis are expected to participate.

NCT Number	NCT07719530
Lead Sponsor	Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions	Psoriasisol
Enrollment	60 participants
Start Date	2026-08-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-22